David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&hl=en_US&gl=US
Author: Editor
Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.
Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.
Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.
Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.
Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…
Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…
Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children’s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children with…
Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children ‘s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…
Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…
Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…
Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.
Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.
Paolo Ghia earned his medical degree from the University of Torino and then completed an internal medicine residency. He earned his PhD studying the formation of normal human B cells at the Basel Institute for Immunology in Basel, Switzerland. He then went to Harvard Medical School’s Dana-Farber Cancer Institute in Boston, where he examined the molecular processes of chronic lymphoproliferative diseases, including follicular lymphoma. He is now a Full Professor of Medical Oncology at Università Vita-Salute San Raffaele and Deputy Chairman of the Division of Experimental Oncology at IRCCS Ospedale San Raffaele in Milano, where he is also Head of…
Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.  He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the affiliated Hospital, where he is Director of the Strategic Research Program on CLL, including a dedicated unit for…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…
Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…
Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…
Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…
Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…
Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.
Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.
Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…
Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…
Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.
Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…
Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…
Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…
Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.
Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCLÂÂÂ-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCLÂÂÂ-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…
Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA StudyLink to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of bortezomib,…
Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…
Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…
Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study.Link to Abstract- https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology and; Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…
Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…
Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…
Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…
Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…
James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…
James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…
Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.
Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.
Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…
Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…
Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…
Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…
Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…
Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…
Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…
Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…
Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…
Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…
Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…
Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…
Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…
Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…
Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…
Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…
Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…
Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…
Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?
Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?
Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…
Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…
Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos ClÃnicos. Para este video, los doctores Velázquez y Franco analizan por qué deberÃa participar en un ensayo clÃnico y cómo. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ********************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our Spanish-speaking community on Clinical Trials.…
¿Qué son los estudios clÃnicos? What are Clinical Trials? Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos ClÃnicos. Para este video, los doctores Velázquez y Franco analizan exactamente qué es un ensayo clÃnico. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ******************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our…
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the cost of clinical trials, billing practices, emergency treatment, and other expenses. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discussclinical trials and provisions or resources for stress and mental health. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what happens if you have to leave a clinical trial. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss if a trial could be the right fit even if your doctor doesn’t know about it. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss potential side effects you might expect on a clinical trial and how you manage them. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please…
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how being on a clinical trial can potentially impact your daily life. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss eligibility for clinical trials. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what a ‘first-in-human’ trial means, and whether participants are a ‘guinea pig’. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss placebos and their use in phase 1 clinical trials, and how it differs from other phases. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the phases of clinical trials and what they mean. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how medical data will be used and if it would be used without the participant’s knowledge. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss whether clinical trials are only for people who have no other options. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
¿Que es la radioterapia, cuando es utilizada, y cuales son los efectos secundarios más comunes?La Dra. Ivy Franco, participante en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tiene una discusión para nuestra comunidad de habla hispana sobre la radioterapia.Para este video, el Dr. Franco analiza qué es la radioterapia, cuándo se usa y cuáles son algunos de los efectos secundarios comunes.¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech!Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.************************************************************************Dr. Ivy Franco, a participant in this past year’s GRACE Patient Education Ambassador Program, has…
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Antibody-Drug Conjugate Treatment Options #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lilly To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard In this video, Drs. Gupta and Lin discuss signs and symptoms that may indicate brain metastases in…
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect after surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, and Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard. In this video, Drs. Gupta and Lin discuss the risks of developing brain metastases in breast…
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard In this video, Drs. Gupta and Lin discuss the prognosis and impact on survival in breast cancer…
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss body image and reconstructive surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect during surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss surgical management in breast cancer, and the surgical removal of lymph nodes – sentinel lymph node biopsy vs. axillary lymph node dissection (ALND). #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss surgical management in breast cancer and prophylactic mastectomy on the opposite breast. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, has presented GRACE with a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss long term outcomes in breast-conserving therapy vs. mastectomy. Many thanks to our sponsors #Lilly and #Genentech! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss the role of different types of surgery and the management of patients with breast cancer. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses TKIs for a…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses ROS1+ patients who…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses the differences in…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses how treatment would…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses what we know…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses whether ROS1+ patients…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses using circulating tumor…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses the next treatment…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses what is next…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ROS session from the event, the panel discusses what information we…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses the reducing dosage…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…
En esta serie de videos, los Dres. Luis Raez, Estalemari Rodriguez y Ticiana Leal tener discusiones sinceras sobre el cáncer y COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clÃnica, los médicos se sentaron para discutir algunas de las preguntas que todos escuchamos sobre estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al impacto de la pandemia COVID-19 en la atención de los pacientes con cáncer. Gracias a Exelixis y Merck por su apoyo a este programa. Para obtener más información, visite…
En esta serie de videos, los Dres. Luis Raez, Estalemari Rodriguez y Ticiana Leal tener discusiones sinceras sobre el cáncer y COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clÃnica, los médicos se sentaron a discutir algunas de las preguntas que todos escuchamos con respecto a estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al uso de la telemedicina en el tratamiento de pacientes con cáncer. Gracias a #Exelixis y #Merck por su apoyo a este programa. Para obtener más información, visite…
En esta serie de videos, los Dres. Luis Raez, Estalemari RodrÃguez y Ticiana Leal tienen conversaciones sinceras sobre el cáncer y el COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clÃnica, los médicos se sentaron a discutir algunas de las preguntas que todos escuchamos con respecto a estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al uso de la vacuna COVID-19 en pacientes con cáncer. Gracias a #Exelixis y #Merck por su apoyo a este programa. Para obtener más información, visite https://cancergrace.org.…
Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division of Hematology/Oncology at the University of California, Irvine, Senior Associate Dean & Associate Vice Chancellor for Cancer University of California, Irvine speaks about Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiverâ„¢ for Early Liver Cancer Detection.Link to Article:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-announce-late-breaking-positive-performance-data-of-helioliver-for-early-liver-cancer-detection-301418252.htmlHelio Health and its commercial partner, Fulgent Genetics, Inc., presented fresh data at AASLD today proving the effectiveness of HelioLiver in detecting hepatocellular carcinoma in its early stages (HCC). HelioLiver’s sensitivity was 76 percent in early-stage HCC and 85…
Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division of Hematology/Oncology at the University of California, Irvine, Senior Associate Dean & Associate Vice Chancellor for Cancer University of California, Irvine speaks about Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiverâ„¢ for Early Liver Cancer Detection.Link to Article:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-announce-late-breaking-positive-performance-data-of-helioliver-for-early-liver-cancer-detection-301418252.htmlHelio Health and its commercial partner, Fulgent Genetics, Inc., presented fresh data at AASLD today proving the effectiveness of HelioLiver in detecting hepatocellular carcinoma in its early stages (HCC). HelioLiver’s sensitivity was 76 percent in early-stage HCC and 85…
Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering speak about New Imaging Technology Developed by UCLA Research Team May Reduce Need for Skin Biopsies.Link to Article:https://samueli.ucla.edu/new-imaging-technology-developed-by-ucla-research-team-may-reduce-need-for-skin-biopsies/Your dermatologist takes photographs of a suspicious-looking lesion and rapidly produces a detailed, microscopic image of the skin instead of surgically extracting a sample of skin, sending it to a lab, and waiting several days for findings.According to a new article published today in Light: Science & Applications, a journal of the Springer Nature Group, this could become commonplace in clinics as a…
Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering speak about New Imaging Technology Developed by UCLA Research Team May Reduce Need for Skin Biopsies.Link to Article:https://samueli.ucla.edu/new-imaging-technology-developed-by-ucla-research-team-may-reduce-need-for-skin-biopsies/Your dermatologist takes photographs of a suspicious-looking lesion and rapidly produces a detailed, microscopic image of the skin instead of surgically extracting a sample of skin, sending it to a lab, and waiting several days for findings.According to a new article published today in Light: Science & Applications, a journal of the Springer Nature Group, this could become commonplace in clinics as a…
Kevan Shokat, Ph.D., Professor, Department of Cellular and Molecular Pharmacology, at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute for discovering a method to inhibit the mutant KRAS protein – a common driver of the growth of lung cancer as well as colorectal and pancreatic cancer. Speaks about Kevan Shokat Ph.D. To Be Awarded The First SWCRF Breakthrough Science Award.Link to Article:https://www.waxmancancer.org/about-us/newsroom/press-releases/kevan-shokat-ph-d-to-be-awarded-the-first-swcrf-breakthrough-science-award/Dr. Kevan Shokat, Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute, will receive the Samuel Waxman Cancer Research Foundation’s first…
John Mascarenhas, MD from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.Link to Abstract:https://www.businesswire.com/news/home/20211112005909/en/U.S.-FDA-Approves-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-the-Only-Interferon-for-Adults-With-Polycythemia-VeraThe US Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera. PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan, is leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology (PV).BESREMi is a novel monopegylated, long-acting interferon that has been shown to have cellular effects on polycythemia vera bone marrow. BESREMi…
John Mascarenhas, MD from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.Link to Abstract:https://www.businesswire.com/news/home/20211112005909/en/U.S.-FDA-Approves-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-the-Only-Interferon-for-Adults-With-Polycythemia-VeraThe US Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera. PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan, is leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology (PV).BESREMi is a novel monopegylated, long-acting interferon that has been shown to have cellular effects on polycythemia vera bone marrow. BESREMi…
Kevan Shokat, Ph.D., Professor, Department of Cellular and Molecular Pharmacology, at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute for discovering a method to inhibit the mutant KRAS protein – a common driver of the growth of lung cancer as well as colorectal and pancreatic cancer. Speaks about Kevan Shokat Ph.D. To Be Awarded The First SWCRF Breakthrough Science Award.Link to Article:https://www.waxmancancer.org/about-us/newsroom/press-releases/kevan-shokat-ph-d-to-be-awarded-the-first-swcrf-breakthrough-science-award/Dr. Kevan Shokat, Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute, will receive the Samuel Waxman Cancer Research Foundation’s first…
Dea Slade, BSc, MSc, Ph.D., Junior group leader, Max F. Perutz Laboratories, University of Vienna speaks about PHF3 regulates neuronal gene expression through the Pol II CTD reader domain SPOC.Link to Abstract:https://www.nature.com/articles/s41467-021-26360-2Abstract:The C-terminal domain (CTD) of RNA polymerase II (Pol IIbiggest )’s subunit is a transcription and RNA processing control center. PHD-finger protein 3 (PHF3) is a transcription and mRNA stability regulator that binds onto the Pol II CTD via its SPOC domain. SPOC is a CTD reader domain that binds two phosphorylated Serine-2 tags in neighboring CTD repeats preferentially. PHF3 promotes the separation of phosphorylated Pol II into liquid…
Dea Slade, BSc, MSc, Ph.D., Junior group leader, Max F. Perutz Laboratories, University of Vienna speaks about PHF3 regulates neuronal gene expression through the Pol II CTD reader domain SPOC.Link to Abstract:https://www.nature.com/articles/s41467-021-26360-2Abstract:The C-terminal domain (CTD) of RNA polymerase II (Pol IIbiggest )’s subunit is a transcription and RNA processing control center. PHD-finger protein 3 (PHF3) is a transcription and mRNA stability regulator that binds onto the Pol II CTD via its SPOC domain. SPOC is a CTD reader domain that binds two phosphorylated Serine-2 tags in neighboring CTD repeats preferentially. PHF3 promotes the separation of phosphorylated Pol II into liquid…
Dr. Erika Hamilton of Sarah Cannon Research Institute chats with Drs. West & Aggarwal about how clinical trials & medical practice have changed after COVID-19, how the field of breast cancer has evolved, & how social media has created a global community.
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care at Mallinckrodt. Speaks about Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults.Link to Article:https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=28736https://therakos.eu/Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis, and cellular technologies, as well as the exclusive distributor of the Therakos extracorporeal photopheresis (ECP) platform in Australia, announced today that the…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care at Mallinckrodt. Speaks about Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults.Link to Article:https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=28736https://therakos.eu/Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis, and cellular technologies, as well as the exclusive distributor of the Therakos extracorporeal photopheresis (ECP) platform in Australia, announced today that the…
Ethan Basch, MD, MSc from Lineberger Comprehensive Cancer Center, University of North Carolina speaks about Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. Â Link to Abstract: https://ascopubs.org/doi/10.1200/CCI.20.00081 Â Â ABSTRACT Â PURPOSE Â During ordinary oncology practice, there is growing interest in using digital tools for remote monitoring of patients’ symptoms. The therapeutic value and user impressions of these devices are both unknown. Â METHODS Â PRO-TECT is a multicenter experiment assessing the use of electronic patient-reported outcomes (ePROs) in persons with advanced and…
Ethan Basch, MD, MSc from Lineberger Comprehensive Cancer Center, University of North Carolina speaks about Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. Â Link to Abstract: https://ascopubs.org/doi/10.1200/CCI.20.00081 Â Â ABSTRACT Â PURPOSE Â During ordinary oncology practice, there is growing interest in using digital tools for remote monitoring of patients’ symptoms. The therapeutic value and user impressions of these devices are both unknown. Â METHODS Â PRO-TECT is a multicenter experiment assessing the use of electronic patient-reported outcomes (ePROs) in persons with advanced and…
Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. Link to Article:https://newsroom.clevelandclinic.org/2021/10/28/cleveland-clinic-study-links-gut-microbiome-and-aggressive-prostate-cancer/For the first time, Cleveland Clinic researchers have discovered that diet-related chemicals in the stomach are linked to aggressive prostate cancer, implying that dietary changes could help reduce risk. The study’s findings were published in the journal Cancer Epidemiology, Biomarkers & Prevention.While further research is needed, lead author Nima Sharifi, M.D., believes the findings from the team’s review of over 700 individuals could have…
Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort.Link to Article:https://newsroom.clevelandclinic.org/2021/10/28/cleveland-clinic-study-links-gut-microbiome-and-aggressive-prostate-cancer/For the first time, Cleveland Clinic researchers have discovered that diet-related chemicals in the stomach are linked to aggressive prostate cancer, implying that dietary changes could help reduce risk. The study’s findings were published in the journal Cancer Epidemiology, Biomarkers & Prevention.While further research is needed, lead author Nima Sharifi, M.D., believes the findings from the team’s review of over 700 individuals could have therapeutic…
Dr. Leora Horn, having recently moved from academic medicine to AstraZeneca, talks with hosts Charu Aggarwal & Jack West about the decision to change roles, her efforts to balance work & family, & how to cultivate opportunities for junior faculty.
Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…
Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…
Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…
Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…
Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…
Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…
Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital & Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…
Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital and Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…
Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…
Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…
Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…
Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…
Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…
Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…
Dr. Lorenzo Gervaso works in the Division of Gastrointestinal Medical Oncology and Neuroendocrnine Tumors at the European Institute of Oncology in Milan Italy. In this video Dr. Gervaso discusses Venous and Arterial Thromboembolism in Patients With Cancer.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.03.001AbstractIn cancer patients, venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality. Myocardial infarction and stroke are common complications of arterial thromboembolism. Subgroups of people are more at risk, with greater rates of cancers such pancreatic, stomach, and multiple myeloma. Most patients with active cancer who are hospitalized for medical reasons or…
Dr. Lorenzo Gervaso works in the Division of Gastrointestinal Medical Oncology and Neuroendocrnine Tumors at the European Institute of Oncology in Milan Italy. In this video Dr. Gervaso discusses Venous and Arterial Thromboembolism in Patients With Cancer.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.03.001AbstractIn cancer patients, venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality. Myocardial infarction and stroke are common complications of arterial thromboembolism. Subgroups of people are more at risk, with greater rates of cancers such pancreatic, stomach, and multiple myeloma. Most patients with active cancer who are hospitalized for medical reasons or…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research Program speaks about ASTRO 2021 Abstract – 94 Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/5dd0f31e-127e-4877-91e4-f2ff0571e5d5- The bodyPurpose/Objective(s):PSA levels before salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) are crucial prognostic and predictive factors after prostate surgery. GC has the ability to independently predict prostate cancer outcomes and may aid in the individualization of treatment. The role of the GC in patients treated in…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research Program speaks about ASTRO 2021 Abstract – 94 Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/5dd0f31e-127e-4877-91e4-f2ff0571e5d5- The bodyPurpose/Objective(s):PSA levels before salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) are crucial prognostic and predictive factors after prostate surgery. GC has the ability to independently predict prostate cancer outcomes and may aid in the individualization of treatment. The role of the GC in patients treated in…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about the ATA 2021 Abstract – Long-term Efficacy and Safety of Larotrectinib in Pts with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://virtual.oxfordabstracts.com/#/event/public/2083/submission/169Body of the Abstract:Goal:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor that has a 75 percent objective response rate (ORR) in 206 evaluable adult and pediatric patients with non-primary CNS malignancies (Hong et al, ASCO 2021). In an extended cohort with longer follow-up, we report on the…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about the ATA 2021 Abstract – Long-term Efficacy and Safety of Larotrectinib in Pts with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://virtual.oxfordabstracts.com/#/event/public/2083/submission/169Body of the Abstract:Goal:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor that has a 75 percent objective response rate (ORR) in 206 evaluable adult and pediatric patients with non-primary CNS malignancies (Hong et al, ASCO 2021). In an extended cohort with longer follow-up, we report on the…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about ESMO 2021 – Abstract – 534P – Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status – and – Long-term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/534P.html.pdfBackground:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor approved in over 40 countries and by the European Medicines Agency for the treatment of TRK fusion cancer in adults…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about ESMO 2021 – Abstract – 534P – Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status – and – Long-term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/534P.html.pdfBackground:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor approved in over 40 countries and by the European Medicines Agency for the treatment of TRK fusion cancer in adults…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising in Younger Women.Link to Article:https://www.cedars-sinai.org/newsroom/study-incidence-of-pancreatic-cancer-rising-in-younger-women/Link to Jama Abstract:https://jamanetwork.com/journals/jama/fullarticle/2785590?resultClick=1 Researchers at Cedars-Sinai Cancer Center discovered that the incidence of pancreatic cancer, which has historically been higher in males than in women, has grown in both men and women over the last decade, with a considerably higher proportional increase among younger women.According to the findings, the average annual percentage change in total pancreatic cancer cases grew by 0.78 percent in women and 0.90 percent in males, with no statistically significant difference between…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising in Younger Women.Link to Article:https://www.cedars-sinai.org/newsroom/study-incidence-of-pancreatic-cancer-rising-in-younger-women/Link to Jama Abstract:https://jamanetwork.com/journals/jama/fullarticle/2785590?resultClick=1 Researchers at Cedars-Sinai Cancer Center discovered that the incidence of pancreatic cancer, which has historically been higher in males than in women, has grown in both men and women over the last decade, with a considerably higher proportional increase among younger women.According to the findings, the average annual percentage change in total pancreatic cancer cases grew by 0.78 percent in women and 0.90 percent in males, with no statistically significant difference between…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline.Link to Article:https://www.panthera-bio.com/news/At the Rutherford Cancer Centre North East, the first multisite oncology trial conducted by the independent sector in the UK has begun treating its first patient. This collaboration between Rutherford Health and Panthera will increase the UK’s capacity to conduct oncology research and give cancer patients more treatment alternatives. More than ten other oncology trials are currently in the works for the…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline.Link to Article:https://www.panthera-bio.com/news/At the Rutherford Cancer Centre North East, the first multisite oncology trial conducted by the independent sector in the UK has begun treating its first patient. This collaboration between Rutherford Health and Panthera will increase the UK ‘s capacity to conduct oncology research and give cancer patients more treatment alternatives. More than ten other oncology trials are currently in the works for…
Hossein Taghizadeh, MD-PhD from the Medical University of Vienna; University Hospital of St. Poelten speaks about MAP 2021 Abstract – 20P – Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors.Link to Abstract:https://cslide.ctimeetingtech.com/map2021_virtual/attendee/confcal_1/presentationBackground:Based on the particular molecular profiles of extensively pretreated cancer patients following failure of all traditional treatments, we investigated the efficacy, feasibility, and limitations of using mTOR inhibitors.Methods:We looked at the genetic characteristics of 70 cancer patients in this single-center, real-world retrospective analysis of our precision medicine platform. Next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry were used to examine tumor…
Hossein Taghizadeh, MD-PhD from the Medical University of Vienna; University Hospital of St. Poelten speaks about MAP 2021 Abstract – 20P – Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors.Link to Abstract:https://cslide.ctimeetingtech.com/map2021_virtual/attendee/confcal_1/presentationBackground:Based on the particular molecular profiles of extensively pretreated cancer patients following failure of all traditional treatments, we investigated the efficacy, feasibility, and limitations of using mTOR inhibitors.Methods:We looked at the genetic characteristics of 70 cancer patients in this single-center, real-world retrospective analysis of our precision medicine platform. Next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry were used to examine tumor…
Dr. Farhat Latif Khanim, Ph.D., and Professor Chris Bunce, BSc, Ph.D., along with Professor Mark Drayson MBChB Ph.D. FRCPath from the University of Birmingham speak about Triple-drug combo could prove key weapon in fight against cancer.  This is only been researched in MDS.  Link to Article: https://www.birmingham.ac.uk/news/latest/2021/10/triple-drug-combo-in-fight-against-cancer.aspx  MDS affects around 7,000 people in the UK, and many patients die as a result of the disease progressing to acute myeloid leukaemia (AML), a more severe blood cancer. AML has a terrible prognosis in general, but it’s even worse when it’s caused by MDS.  AML kills patients swiftly…
Dr. Farhat Latif Khanim, Ph.D., and Professor Chris Bunce, BSc, Ph.D., along with Professor Mark Drayson MBChB Ph.D. FRCPath from the University of Birmingham speak about Triple-drug combo could prove key weapon in fight against cancer.  This is only been researched in MDS.  Link to Article: https://www.birmingham.ac.uk/news/latest/2021/10/triple-drug-combo-in-fight-against-cancer.aspx  MDS affects around 7,000 people in the UK, and many patients die as a result of the disease progressing to acute myeloid leukaemia (AML), a more severe blood cancer. AML has a terrible prognosis in general, but it’s even worse when it’s caused by MDS.  AML kills patients swiftly…
Andrew J. Brenner MD, Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECTâ„¢ clinical trial speaks about Rhenium-186 NanoLiposome (186RNL) from its ReSPECTâ„¢ clinical trial in recurrent glioblastoma (GBM).Link to Study:https://s24.q4cdn.com/705376798/files/doc_presentations/2021/08/Brenner_LMD-13_ReSPECT-LM-Maximum-tolderated-dose-safety-and-efficacy-of-intraventricular-Rhenium-186-Nanoliposome-(186RNL)-for.pdfDesign of the Study:• A multi-center, open-label, dose-escalation study assessing the safety, tolerability, and distribution of 186RNL through intrathecal infusion to the ventricle in patients with LM after routine surgical, radiation, and/or chemotherapy treatment.• With a starting dose of 6.6 mCi in a volume of 5 mL, a modified Fibonacci dose escalation was used,…
Andrew J. Brenner MD, Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECTâ„¢ clinical trial speaks about Rhenium-186 NanoLiposome (186RNL) from its ReSPECTâ„¢ clinical trial in recurrent glioblastoma (GBM).Link to Study:https://s24.q4cdn.com/705376798/files/doc_presentations/2021/08/Brenner_LMD-13_ReSPECT-LM-Maximum-tolderated-dose-safety-and-efficacy-of-intraventricular-Rhenium-186-Nanoliposome-(186RNL)-for.pdfDesign of the Study:• A multi-center, open-label, dose-escalation study assessing the safety, tolerability, and distribution of 186RNL through intrathecal infusion to the ventricle in patients with LM after routine surgical, radiation, and/or chemotherapy treatment.• With a starting dose of 6.6 mCi in a volume of 5 mL, a modified Fibonacci dose escalation was used,…
Aaron L. Schwartz, MD, Ph.D., Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania speaks about Measuring the Scope of Prior Authorization Policies – Applying Private Insurer Rules to Medicare Part B.Link to Abstract:https://jamanetwork.com/journals/jama-health-forum/fullarticle/2780396Points to Remember -Question: How common are medical services that require prior authorization and how much do they cost?Findings:This cross-sectional study looked at medical services paid for by government-administered Medicare Part B, which doesn’t require prior authorization, for about 6.5 million beneficiaries. The study found that 2.2 services per beneficiary per year would have required prior authorization under the coverage…
Aaron L. Schwartz, MD, Ph.D., Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania speaks about Measuring the Scope of Prior Authorization Policies – Applying Private Insurer Rules to Medicare Part B.Link to Abstract:https://jamanetwork.com/journals/jama-health-forum/fullarticle/2780396Points to Remember -Question: How common are medical services that require prior authorization and how much do they cost?Findings:This cross-sectional study looked at medical services paid for by government-administered Medicare Part B, which doesn’t require prior authorization, for about 6.5 million beneficiaries. The study found that 2.2 services per beneficiary per year would have required prior authorization under the coverage…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center speaks about the ASTRO 2021 Abstract Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/3a92a692-4d67-4c3e-8090-17b848cb1ee5Body:Purpose/Objective(s):To analyze the impact of androgen deprivation therapy (ADT) use and duration with definitive radiotherapy (RT) in localized prostate cancer in the first global individual patient data (IPD) meta-analysis of randomized trials.Materials/Methods:International trial groups (NRG/RTOG,…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center speaks about the ASTRO 2021 Abstract Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/3a92a692-4d67-4c3e-8090-17b848cb1ee5Body:Purpose/Objective(s):To analyze the impact of androgen deprivation therapy (ADT) use and duration with definitive radiotherapy (RT) in localized prostate cancer in the first global individual patient data (IPD) meta-analysis of randomized trials.Materials/Methods:International trial groups (NRG/RTOG,…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive Function Following Concurrent Radiotherapy and Temozolomide for Adult Patients With Low-Grade Glioma.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/27f970a0-a161-48c6-adc4-064924c2d044Case:Goal:RTOG 0424 showed that patients with high-risk low-grade glioma (LGG) who received concurrent temozolomide (TMZ) and radiation (RT) followed by adjuvant temozolomide (RT+TMZ) had a longer life than historical controls. The long-term effects of this therapy method on neurocognitive results are unknown. We wanted to see how neurocognitive parameters changed in adult LGG patients before and after RT+TMZ.Components:We looked at 22 LGG patients who had been treated…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive Function Following Concurrent Radiotherapy and Temozolomide for Adult Patients With Low-Grade Glioma.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/27f970a0-a161-48c6-adc4-064924c2d044Case:Goal:RTOG 0424 showed that patients with high-risk low-grade glioma (LGG) who received concurrent temozolomide (TMZ) and radiation (RT) followed by adjuvant temozolomide (RT+TMZ) had a longer life than historical controls. The long-term effects of this therapy method on neurocognitive results are unknown. We wanted to see how neurocognitive parameters changed in adult LGG patients before and after RT+TMZ.Components:We looked at 22 LGG patients who had been treated…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.Link to Article:https://www.sciencedirect.com/science/article/pii/S0302283821020595Summary -Origins:The discovery of germline mutations in DNA repair genes has major implications for the personalized treatment of prostate cancer patients (PrCa).Mission:Determine the genetic testing burden and identify DNA repair genes associated with localized PrCa in a diverse academic biobank.Participants, setting, and design:A cross-sectional study of 2391 PrCa patients with localized PrCa was conducted.Measurement of outcomes and statistical analysis:In 1588 localized PrCa patients and 3273 cancer-free males, genetic ancestry and mutation rates…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.Link to Article:https://www.sciencedirect.com/science/article/pii/S0302283821020595Summary -Origins:The discovery of germline mutations in DNA repair genes has major implications for the personalized treatment of prostate cancer patients (PrCa).Mission:Determine the genetic testing burden and identify DNA repair genes associated with localized PrCa in a diverse academic biobank.Participants, setting, and design:A cross-sectional study of 2391 PrCa patients with localized PrCa was conducted.Measurement of outcomes and statistical analysis:In 1588 localized PrCa patients and 3273 cancer-free males, genetic ancestry and mutation rates…
John C. Breneman, MD, principal investigator, and Medical Director of the Cincinnati Children’s/UC Health Proton Therapy Center, UC Health radiation oncologist, and professor emeritus at the University of Cincinnati College of Medicine The trial is supported by Emily Daugherty, M.D., assistant professor of radiation oncology at UC and a UC Health radiation oncologist, and Anthony Mascia, Ph.D., DABR, adjunct assistant professor of radiation oncology at UC and Director of Medical Physics at the Cincinnati Children’s/UC Health Proton Therapy Center and John Perentesis, MD, Directory of Pediatric Oncology, Cincinnati Children’s Hospital. Speaks about Varian and the Cincinnati Children’s/UC Health Proton Therapy…
John C. Breneman, MD, principal investigator, and Medical Director of the Cincinnati Children’s/UC Health Proton Therapy Center, UC Health radiation oncologist, and professor emeritus at the University of Cincinnati College of Medicine The trial is supported by Emily Daugherty, M.D., assistant professor of radiation oncology at UC and a UC Health radiation oncologist, and Anthony Mascia, Ph.D., DABR, adjunct assistant professor of radiation oncology at UC and Director of Medical Physics at the Cincinnati Children’s/UC Health Proton Therapy Center and John Perentesis, MD, Directory of Pediatric Oncology, Cincinnati Children’s Hospital. Speaks about Varian and the Cincinnati Children’s/UC Health Proton Therapy…
Karen Winkfield, MD, Ph.D. is the executive director of the Meharry-Vanderbilt Alliance, professor of Radiation Oncology and Ingram Professor of Cancer Research at Vanderbilt University Medical Center, and professor of Medicine at Meharry Medical College speaks about President Biden appoints Karen Winkfield to National Cancer Advisory Board. Link to Article:https://www.newswise.com/articles/president-biden-appoints-karen-winkfield-to-national-cancer-advisory-boardKaren Winkfield, MD, Ph.D., has been named by President Joe Biden to the National Cancer Advisory Board, where she will serve a six-year term and help steer federal cancer activities.The board advises the Secretary of the United States Department of Health and Human Services and the Director of the National Cancer…
Karen Winkfield, MD, Ph.D. is the executive director of the Meharry-Vanderbilt Alliance, professor of Radiation Oncology and Ingram Professor of Cancer Research at Vanderbilt University Medical Center, and professor of Medicine at Meharry Medical College speaks about President Biden appoints Karen Winkfield to National Cancer Advisory Board. Link to Article:https://www.newswise.com/articles/president-biden-appoints-karen-winkfield-to-national-cancer-advisory-boardKaren Winkfield, MD, Ph.D., has been named by President Joe Biden to the National Cancer Advisory Board, where she will serve a six-year term and help steer federal cancer activities.The board advises the Secretary of the United States Department of Health and Human Services and the Director of the National Cancer…
Chirag Shah, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 66 Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/b6437add-873a-4710-b4bd-0153a3d5cb8bIntention:There is an unmet need to identify women with DCIS who have a low recurrence risk and could avoid radiotherapy (RT) after breast-conserving surgery (BCS), as well as those who have a high recurrence risk after BCS plus RT.Components:At sites in Sweden, the United States, and Australia, pathology, clinical data, and FFPE tissue samples were evaluated for 485 women treated for DCIS with…
Chirag Shah, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 66 Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/b6437add-873a-4710-b4bd-0153a3d5cb8bIntention:There is an unmet need to identify women with DCIS who have a low recurrence risk and could avoid radiotherapy (RT) after breast-conserving surgery (BCS), as well as those who have a high recurrence risk after BCS plus RT.Components:At sites in Sweden, the United States, and Australia, pathology, clinical data, and FFPE tissue samples were evaluated for 485 women treated for DCIS with…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation Oncology, Radiation Oncology, Dana-Farber Cancer Institute, Dana-Farber|Harvard Cancer Center speaks about ASTRO 2021 Abstract – 95 Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/0d611c23-3eee-4918-bdcf-3cadc805a0b7Link to Study:https://clinicaltrials.gov/ct2/show/NCT04513717Objective:Decipher is a prognostic 22-gene genomic classifier (GC) that has been prospectively verified after prostate surgery. In this study, we used three randomized phase III high-risk definitive radiotherapy trials to confirm the GC’s…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation Oncology, Radiation Oncology, Dana-Farber Cancer Institute, Dana-Farber|Harvard Cancer Center speaks about ASTRO 2021 Abstract – 95 Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/0d611c23-3eee-4918-bdcf-3cadc805a0b7Link to Study:https://clinicaltrials.gov/ct2/show/NCT04513717Objective:Decipher is a prognostic 22-gene genomic classifier (GC) that has been prospectively verified after prostate surgery. In this study, we used three randomized phase III high-risk definitive radiotherapy trials to confirm the GC’s…
Samuel Chao, MD Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 51 18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis From Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery: Results of a Prospective Pilot Study.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/46e4dee0-17bf-49b9-a92f-6097130183e1Intention:To present the findings of a prospective pilot study using 18F Fluciclovine PET CT to discriminate radiation necrosis (RN) from tumor progression (TP) in patients with brain metastases (BM) treated with stereotactic radiosurgery (SRS).Components:The main goal was to determine how accurate 18F Fluciclovine PET CT was at distinguishing RN from TP. Adults with BM who had SRS…
Samuel Chao, MD Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 51 18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis From Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery: Results of a Prospective Pilot Study.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/46e4dee0-17bf-49b9-a92f-6097130183e1Intention:To present the findings of a prospective pilot study using 18F Fluciclovine PET CT to discriminate radiation necrosis (RN) from tumor progression (TP) in patients with brain metastases (BM) treated with stereotactic radiosurgery (SRS).Components:The main goal was to determine how accurate 18F Fluciclovine PET CT was at distinguishing RN from TP. Adults with BM who had SRS…
Jelena Lukovic, MD, FRCPC, MPH, Radiation Onologist, University of Toronto, Princess Margaret Cancer Centre speaks about the ASTRO 2021 Abstract – 73 The Feasibility of Quality Assurance in the TOPGEAR International Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy for Gastric Cancer (An Intergroup Trial of the AGITG/TROG/EORTC/CCTG).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/ab077756-3746-4723-8871-8f9b1cfa329bAbstract:Intention:The TOPGEAR (Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma) worldwide phase III trial hypothesized that supplementing perioperative chemotherapy with preoperative chemoradiation (CRT) would enhance survival in patients with gastric cancer. A sophisticated radiation therapy quality assurance (RTQA) methodology was created due to the intricacy of stomach irradiation. The purpose…
Jelena Lukovic, MD, FRCPC, MPH, Radiation Onologist, University of Toronto, Princess Margaret Cancer Centre speaks about the ASTRO 2021 Abstract – 73 The Feasibility of Quality Assurance in the TOPGEAR International Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy for Gastric Cancer (An Intergroup Trial of the AGITG/TROG/EORTC/CCTG).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/ab077756-3746-4723-8871-8f9b1cfa329bAbstract:Intention):The TOPGEAR (Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma) worldwide phase III trial hypothesized that supplementing perioperative chemotherapy with preoperative chemoradiation (CRT) would enhance survival in patients with gastric cancer. A sophisticated radiation therapy quality assurance (RTQA) methodology was created due to the intricacy of stomach irradiation. The purpose…
Michelina Cairo, MD from Texas Oncology speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study (Enhertu).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/trastuzumab-deruxtecan-t-dxd-vs-trastuzumab-emtansine-t-dm1-in-patients-pts-with-her2-metastatic-breast-cancer-mbc-results-of-the-randomiLBA1 Abstract -Background:Based on the outcomes of DESTINY-Breast01, T-DXd is a HER2-targeting antibody-drug conjugate that has been authorized for patients with advanced HER2+ mBC (NCT03248492). DESTINY-Breast03 (NCT03529110) is a multicenter, open-label, randomized phase 3 trial evaluating the effectiveness and safety of T-DXd against T-DM1 in patients with HER2+ mBC who had previously had trastuzumab and taxane treatment. This is the first…
Michelina Cairo, MD from Texas Oncology speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study (Enhertu).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/trastuzumab-deruxtecan-t-dxd-vs-trastuzumab-emtansine-t-dm1-in-patients-pts-with-her2-metastatic-breast-cancer-mbc-results-of-the-randomiLBA1 Abstract -Background:Based on the outcomes of DESTINY-Breast01, T-DXd is a HER2-targeting antibody-drug conjugate that has been authorized for patients with advanced HER2+ mBC (NCT03248492). DESTINY-Breast03 (NCT03529110) is a multicenter, open-label, randomized phase 3 trial evaluating the effectiveness and safety of T-DXd against T-DM1 in patients with HER2+ mBC who had previously had trastuzumab and taxane treatment. This is the first…
Dr. MJ Markham, Chief of Heme-Onc at Univ of Florida, chats with Drs. Charu Aggarwal and Jack West about the intersection of gynecologic & medical oncology, COVID-19 blogging, gender bias, and social media dissemination of new results in cancer care.
Joshua D. Mitchell, MD from Washington University in St. Louis speaks about Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.Link to Abstract:https://www.jacc.org/doi/10.1016/j.jaccao.2021.06.003Summary -Radiation therapy is a cornerstone of cancer treatment, with more than half of patients receiving it. As a result of increased use and survival, researchers are paying more attention to the long-term effects of ionizing radiation, including cardiovascular damage. Radiation therapy can cause vascular atherosclerosis, as well as a valve, cardiac, and pericardial dysfunction. The International Cardio-Oncology Society has issued a consensus statement based on broad principles of radiation treatment, cardiovascular…
Joshua D. Mitchell, MD from Washington University in St. Louis speaks about Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.Link to Abstract:https://www.jacc.org/doi/10.1016/j.jaccao.2021.06.003Summary -Radiation therapy is a cornerstone of cancer treatment, with more than half of patients receiving it. As a result of increased use and survival, researchers are paying more attention to the long-term effects of ionizing radiation, including cardiovascular damage. Radiation therapy can cause vascular atherosclerosis, as well as a valve, cardiac, and pericardial dysfunction. The International Cardio-Oncology Society has issued a consensus statement based on broad principles of radiation treatment, cardiovascular…
Wendy Levin, MD, MS , Chief Medical Officer at Biofidelity speaks about the New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients. Link to Article:https://www.prnewswire.com/news-releases/new-california-law-increases-access-to-biomarker-testing-for-late-stage-cancer-patients-301399084.htmlBiofidelity, a leader in precision cancer diagnostics, applauded California Governor Gavin Newsom and the California legislature for passing SB 535 on October 6th, a bill that prevents health insurers that already cover biomarker testing from requiring prior authorization for patients with advanced-stage cancer.These tailored medicines provide patients with an option to a severe chemotherapy regimen, frequently with better outcomes. Since targeted medicines were accessible in 2010, five-year survival rates for lung cancer have…
Wendy Levin, MD, MS , Chief Medical Officer at Biofidelity speaks about the New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients. Link to Article:https://www.prnewswire.com/news-releases/new-california-law-increases-access-to-biomarker-testing-for-late-stage-cancer-patients-301399084.htmlBiofidelity, a leader in precision cancer diagnostics, applauded California Governor Gavin Newsom and the California legislature for passing SB 535 on October 6th, a bill that prevents health insurers that already cover biomarker testing from requiring prior authorization for patients with advanced-stage cancer.These tailored medicines provide patients with an option to a severe chemotherapy regimen, frequently with better outcomes. Since targeted medicines were accessible in 2010, five-year survival rates for lung cancer have…
John P. Pierce, Ph.D., Professor Emeritus, Moores UCSD Cancer Center speaks about Does switching to e-Cigarettes Prevent Relapse?Link to Abstract:https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785237?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101921Points to Remember -Is switching to e-cigarettes linked to a lower risk of relapsing into cigarette smoking?Findings: In this cohort research of a representative sample of US people, 9.4% of those who smoked cigarettes 1 year later were recent former smokers. Switching to any tobacco product, including e-cigarettes, was linked to an 8.5 percent increase in relapse to smoking over the next year, which was similar to the rise reported in people who moved to conventional tobacco products.Meaning: In adults in…
John P. Pierce, Ph.D., Professor Emeritus, Moores UCSD Cancer Center speaks about Does switching to e-Cigarettes Prevent Relapse?Link to Abstract:https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785237?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101921Points to Remember -Is switching to e-cigarettes linked to a lower risk of relapsing into cigarette smoking?Findings: In this cohort research of a representative sample of US people, 9.4% of those who smoked cigarettes 1 year later were recent former smokers. Switching to any tobacco product, including e-cigarettes, was linked to an 8.5 percent increase in relapse to smoking over the next year, which was similar to the rise reported in people who moved to conventional tobacco products.Meaning: In adults in…
Debra Patt, MD, Ph.D., MBA, FASCO, Executive Vice President at Texas Oncology a member of The US Oncology Network, Professor at Dell Medical School – The University of Texas at Austin speaks about Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting.Link to Article:https://www.nature.com/articles/s41596-021-00617-y.epdf?sharing_token=lzLbY_YpHlRJVJBqHkCe1NRgN0jAjWel9jnR3ZoTv0NL3ac1xHMXQwl5KtvTQSPu9LLHl_s2_RNgf6Ghz02Kzzj0C4_EmzkEElnB1Ukrqfkd1DPgirmLS8j-PffRD8npiNb__zUwr8801sfrYOzQ8Nfjh7QuG_3iWFWAmjQgn28%3DOverview:In a community-based care context, this protocol outlines a complete data acquisition, analysis, and computational forecasting pipeline for using quantitative MRI data to predict the response of locally advanced breast cancer to neoadjuvant therapy. The methodology has been successfully used to a diverse patient group in the past. The protocol explains…
Debra Patt, MD, Ph.D., MBA, FASCO, Executive Vice President at Texas Oncology a member of The US Oncology Network, Professor at Dell Medical School – The University of Texas at Austin speaks about Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting.Link to Article:https://www.nature.com/articles/s41596-021-00617-y.epdf?sharing_token=lzLbY_YpHlRJVJBqHkCe1NRgN0jAjWel9jnR3ZoTv0NL3ac1xHMXQwl5KtvTQSPu9LLHl_s2_RNgf6Ghz02Kzzj0C4_EmzkEElnB1Ukrqfkd1DPgirmLS8j-PffRD8npiNb__zUwr8801sfrYOzQ8Nfjh7QuG_3iWFWAmjQgn28%3DOverview:In a community-based care context, this protocol outlines a complete data acquisition, analysis, and computational forecasting pipeline for using quantitative MRI data to predict the response of locally advanced breast cancer to neoadjuvant therapy. The methodology has been successfully used to a diverse patient group in the past. The protocol explains…
Gregory Vladimer, Ph.D., VP of translational research at Exscientia and co-inventor of the AI-precision medicine platform speaks about Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes. Link to Article:https://investors.exscientia.ai/press-releases/press-release-details/2021/Publication-of-EXALT-1-Trial-in-Cancer-Discovery-Demonstrates-First-AI-Supported-Functional-Precision-Medicine-Platform-to-Improve-Cancer-Treatment-Outcomes/default.aspxFinal results from the EXALT-1 study were published today in Cancer Discovery, a journal of the American Association of Cancer Research, by Exscientia (Nasdaq: EXAI), the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional…
Gregory Vladimer, Ph.D., VP of translational research at Exscientia and co-inventor of the AI-precision medicine platform speaks about Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes. Link to Article:https://investors.exscientia.ai/press-releases/press-release-details/2021/Publication-of-EXALT-1-Trial-in-Cancer-Discovery-Demonstrates-First-AI-Supported-Functional-Precision-Medicine-Platform-to-Improve-Cancer-Treatment-Outcomes/default.aspxFinal results from the EXALT-1 study were published today in Cancer Discovery, a journal of the American Association of Cancer Research, by Exscientia (Nasdaq: EXAI), the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional…
Bijal Shah, MD, MS, ZUMA-3 investigator, and medical oncologist, Moffitt Cancer Center, Tampa, Florida speaks about U.S. FDA Approves Kite’s Tecartus(R) as the First and Only CAR T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.Link to Article:https://www.kitepharma.com/news/press-releases/2021/10/us-fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemiaTecartus® (brexucabtagene autoleucel) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus is the first and only chimeric antigen receptor (CAR) T-cell treatment approved for adults (18 years and older) with ALL, following FDA Breakthrough Therapy Designation and…
Bijal Shah, MD, MS, ZUMA-3 investigator, and medical oncologist, Moffitt Cancer Center, Tampa, Florida speaks about U.S. FDA Approves Kite’s Tecartus(R) as the First and Only CAR T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.Link to Article:https://www.kitepharma.com/news/press-releases/2021/10/us-fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemiaTecartus® (brexucabtagene autoleucel) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus is the first and only chimeric antigen receptor (CAR) T-cell treatment approved for adults (18 years and older) with ALL, following FDA Breakthrough Therapy Designation and…
Stephanie Patterson, MD, FACR, FSBI, Clinical Professor, Radiology, Division of Breast Imaging, University of Michigan, Michigan Medicine speaks about Tomosynthesis Mammographic Imaging Screening Trial (TMIST). This is an ongoing study. Link to Study:www.cancer.gov/tmistTMIST is a randomized breast screening experiment that will aid researchers in determining the best methods for detecting breast cancer in women with no symptoms. It compares two types of digital mammography approved by the Food and Drug Administration (FDA): regular digital mammography (2-D) and tomosynthesis mammography, a newer technology (3-D). To obtain a flat image, 2-D mammography captures photos from two sides of the breast. 3-D mammography…
Stephanie Patterson, MD, FACR, FSBI, Clinical Professor, Radiology, Division of Breast Imaging, University of Michigan, Michigan Medicine speaks about Tomosynthesis Mammographic Imaging Screening Trial (TMIST). This is an ongoing study.Link to Study:www.cancer.gov/tmistTMIST is a randomized breast screening experiment that will aid researchers in determining the best methods for detecting breast cancer in women with no symptoms. It compares two types of digital mammography approved by the Food and Drug Administration (FDA): regular digital mammography (2-D) and tomosynthesis mammography, a newer technology (3-D). To obtain a flat image, 2-D mammography captures photos from two sides of the breast. 3-D mammography images…
Daneng Li, MD from the City of Hope speaks about Older adults who receive additional supportive care services experience fewer side effects from chemotherapy, City of Hope study finds. Link to Article:https://www.cityofhope.org/news/clinical-trial-over-65-chemotherapyWhen a multidisciplinary team of experts analyzed each case and introduced personalized interventions, patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects, according to a clinical trial led by researchers at City of Hope, a world-renowned cancer research and treatment organization.Patients were offered additional supportive care services based on the findings of a cancer-specific geriatric assessment, a thorough instrument created by City of Hope in partnership with…
Daneng Li, MD from the City of Hope speaks about Older adults who receive additional supportive care services experience fewer side effects from chemotherapy, City of Hope study finds. Link to Article:https://www.cityofhope.org/news/clinical-trial-over-65-chemotherapyWhen a multidisciplinary team of experts analyzed each case and introduced personalized interventions, patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects, according to a clinical trial led by researchers at City of Hope, a world-renowned cancer research and treatment organization.Patients were offered additional supportive care services based on the findings of a cancer-specific geriatric assessment, a thorough instrument created by City of Hope in partnership with…
Danny Nguyen, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Orange County Irvine speaks about ESMO 2021 Abstract – 1261MO – Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins).Link to Abstract:https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=1218P+&r=pt%7E53Summary -Backstory:According to the independent review committee (IRC), the phase I/II study (NCT02716116) of mobocertinib 160 mg QD in platinum-pretreated patients (PPP) with EGFRex20ins+ NSCLC showed a verified objective response rate (ORR) of 28 percent; GI toxicities were the most common side events (AEs).Methodologies:We provide ORR, DoR, and PFS per IRC in patients with…
Danny Nguyen, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Orange County Irvine speaks about ESMO 2021 Abstract – 1261MO – Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins).Link to Abstract:https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=1218P+&r=pt%7E53Summary -Backstory:According to the independent review committee (IRC), the phase I/II study (NCT02716116) of mobocertinib 160 mg QD in platinum-pretreated patients (PPP) with EGFRex20ins+ NSCLC showed a verified objective response rate (ORR) of 28 percent; GI toxicities were the most common side events (AEs).Methodologies:We provide ORR, DoR, and PFS per IRC in patients with…
Mario Campone, MD, Ph.D., Professor, Medical Oncologist, Director General of the Institut de Cancérologie de l’Ouest (ICO), René Gauducheau, St Herblain, France speaks about ESMO 2021 Abstract – 264P – AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/ameera-1-subgroup-analyses-of-phase-i-ii-study-of-amcenestrant-sar439859-an-oral-selective-estrogen-receptor-er-degrader-serd-with-palboci264P – AbstractBackstory:Amcenestrant is an optimized, oral SERD that has showed promising anticancer activity in ER+/HER2– aBC when combined with palbociclib (palbo). Updated data, including anticancer activity by subgroups, is shown here.Methodologies:This phase…
Mario Campone, MD, Ph.D., Professor, Medical Oncologist, Director General of the Institut de Cancérologie de l’Ouest (ICO), René Gauducheau, St Herblain, France speaks about ESMO 2021 Abstract – 264P – AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/ameera-1-subgroup-analyses-of-phase-i-ii-study-of-amcenestrant-sar439859-an-oral-selective-estrogen-receptor-er-degrader-serd-with-palboci264P – AbstractBackstory:Amcenestrant is an optimized, oral SERD that has showed promising anticancer activity in ER+/HER2– aBC when combined with palbociclib (palbo). Updated data, including anticancer activity by subgroups, is shown here.Methodologies:This phase…
Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study speaks about the USCLC 2021 Abstract – HyBryteâ„¢ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting.Link to Article:https://www.prnewswire.com/news-releases/hybryte-positive-pivotal-phase-3-flash-study-selected-for-presentation-at-the-united-states-cutaneous-lymphoma-consortium-usclc-annual-meeting-301317045.htmlSoligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for…
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about the AUA 2021 Abstract – MP60-03 ISOPSA: CLINICAL PERFORMANCE OF A SINGLE PARAMETER, STRUCTURE BASED TEST FOR HIGH GRADE PROSTATE CANCER IN A LARGE, MULTICENTER, PROSPECTIVE VALIDATION TRIAL. Link to the Abstract:https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002095.03A Summary -OBJECTIVE AND INTRODUCTION:In a large-scale prospective validation experiment, we offer cumulative results detailing the clinical efficacy of IsoPSA, a blood-based, structure-focused test for high-grade prostate cancer.Methodologies:Blood samples were collected from several clinical sites within 30 days prior to prostate biopsy from patients with serum PSA between 4 and 100 ng/ml in this…
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about the AUA 2021 Abstract – MP60-03 ISOPSA: CLINICAL PERFORMANCE OF A SINGLE PARAMETER, STRUCTURE BASED TEST FOR HIGH GRADE PROSTATE CANCER IN A LARGE, MULTICENTER, PROSPECTIVE VALIDATION TRIAL. Link to the Abstract:https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002095.03A Summary -OBJECTIVE AND INTRODUCTION:In a large-scale prospective validation experiment, we offer cumulative results detailing the clinical efficacy of IsoPSA, a blood-based, structure-focused test for high-grade prostate cancer.Methodologies:Blood samples were collected from several clinical sites within 30 days prior to prostate biopsy from patients with serum PSA between 4 and 100 ng/ml in this…
Kimlin Tam Ashing, PhD, professor in the Department of Population Sciences at City of Hope speaks about The Science Of Cancer Health Disparities In Racial/Ethnic Minorities And The Medically Underserved.Link to Article:https://www.onclive.com/view/clinical-trial-diversity-efforts-gain-steamThe NIH Revitalization Act of 1993 requires that women and members of racial and ethnic minorities be recruited for all NIH-sponsored clinical trials, with enough participants in subpopulations, particularly in phase 3 research, to assess any genuine disparities in outcomes. Researchers who applied for NIH grants were obliged to implement outreach initiatives to guarantee that those objectives were realized.However, when it comes to minorities with cancer, the law has…
Kimlin Tam Ashing, PhD, professor in the Department of Population Sciences at City of Hope speaks about The Science Of Cancer Health Disparities In Racial/Ethnic Minorities And The Medically Underserved.Link to Article:https://www.onclive.com/view/clinical-trial-diversity-efforts-gain-steamThe NIH Revitalization Act of 1993 requires that women and members of racial and ethnic minorities be recruited for all NIH-sponsored clinical trials, with enough participants in subpopulations, particularly in phase 3 research, to assess any genuine disparities in outcomes. Researchers who applied for NIH grants were obliged to implement outreach initiatives to guarantee that those objectives were realized.However, when it comes to minorities with cancer, the law has…
Dr. Jyoti Patel from Lurie Cancer Center, Northwestern University joins Drs. Charu Aggarwal & Jack West to reflect on how to decide when to change institutions, & the evolving methods of providing cancer education, including directly to patients.
Maxim Ivanov, Ph.D. at the Moscow Institute of Physics and Technology, Department of Biological and Medical Physics, Atlas Oncology Diagnostics. Speaks about the ESMO MAP 2021 Abstract – 13P – Incidental germline findings from tumor molecular profiling for precision oncology – is it common and how to manage.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/map-2021/incidental-germline-findings-from-tumor-molecular-profiling-for-precision-oncology-is-it-common-and-how-to-manageAbstract:Background:A small percentage of patients who are referred for tumor-only complex molecular profiling may have germline mutations in genes linked to hereditary cancer syndromes (HCS). The treatment and reporting of such unintentional germline results are not standardized in bioinformatics.Methods:In order to detect germline variations in HCS-associated genes, data from NGS sequencing…
Maxim Ivanov, Ph.D. at the Moscow Institute of Physics and Technology, Department of Biological and Medical Physics, Atlas Oncology Diagnostics. Speaks about the ESMO MAP 2021 Abstract – 13P – Incidental germline findings from tumor molecular profiling for precision oncology – is it common and how to manage.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/map-2021/incidental-germline-findings-from-tumor-molecular-profiling-for-precision-oncology-is-it-common-and-how-to-manageAbstract:Background:A small percentage of patients who are referred for tumor-only complex molecular profiling may have germline mutations in genes linked to hereditary cancer syndromes (HCS). The treatment and reporting of such unintentional germline results are not standardized in bioinformatics.Methods:In order to detect germline variations in HCS-associated genes, data from NGS sequencing…
Prof. Dr. med. Dirk Schadendorf, Universitätsklinikum Essen speaks about the ESMO 2021 Abstract – 1091TiP – STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/starboard-randomized-phase-iii-study-of-encorafenib-enco-binimetinib-bini-pembrolizumab-pembro-for-first-line-treatment-of-metastatic-or1091TiP -Context:BRAF V600 mutations are found in around half of all individuals with metastatic melanoma, and they accelerate melanoma progression by activating the MAPK pathway in a constant state. BRAF inhibitors (BRAFi) + MEK inhibitors (MEKi) (eg, enco + bini) and immune checkpoint inhibitors are now recommended treatments for metastatic or unresectable BRAF V600-mutant melanoma (CPIs; eg,…
Prof. Dr. med. Dirk Schadendorf, Universitätsklinikum Essen speaks about the ESMO 2021 Abstract – 1091TiP – STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/starboard-randomized-phase-iii-study-of-encorafenib-enco-binimetinib-bini-pembrolizumab-pembro-for-first-line-treatment-of-metastatic-or1091TiP -Context:BRAF V600 mutations are found in around half of all individuals with metastatic melanoma, and they accelerate melanoma progression by activating the MAPK pathway in a constant state. BRAF inhibitors (BRAFi) + MEK inhibitors (MEKi) (eg, enco + bini) and immune checkpoint inhibitors are now recommended treatments for metastatic or unresectable BRAF V600-mutant melanoma (CPIs; eg,…
Sameek Roychowdhury, MD, Ph.D., a medical oncologist, and researcher with the OSUCCC – James Translational Therapeutics Research Program speaks about Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Link to Study:https://www.sciencedirect.com/science/article/abs/pii/S2468125321001965Conclusion -Brief history:After advancement on first-line gemcitabine-based therapy, individuals with advanced cholangiocarcinoma have few treatment alternatives. In 10–16 percent of individuals with intrahepatic cholangiocarcinoma, FGFR2 fusions or rearrangements are found. Infigratinib is a fibroblast growth factor receptor inhibitor that is selective and ATP-competitive. The researchers wanted to see if infigratinib had an antitumor…
Sameek Roychowdhury, MD, Ph.D., a medical oncologist, and researcher with the OSUCCC – James Translational Therapeutics Research Program speaks about Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Link to Study:https://www.sciencedirect.com/science/article/abs/pii/S2468125321001965Conclusion -Brief history:After advancement on first-line gemcitabine-based therapy, individuals with advanced cholangiocarcinoma have few treatment alternatives. In 10–16 percent of individuals with intrahepatic cholangiocarcinoma, FGFR2 fusions or rearrangements are found. Infigratinib is a fibroblast growth factor receptor inhibitor that is selective and ATP-competitive. The researchers wanted to see if infigratinib had an antitumor…
Sudipto Mukherjee, MD, MPH, Ph.D., Director of Rare Cancers and Blood Diseases, at the Cleveland Clinic speaks about the Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy.Link to Article:https://doi.org/10.1182/bloodadvances.2021004441Points to Remember:* To calculate the incidence and prevalence of iMCD, a novel algorithm based on disease-specific ICD-10-CM codes and diagnostic criteria were developed.* Despite being the only FDA-approved medication, siltuximab is rarely used in iMCD patients.The epidemiology of HHV-8-deficient/idiopathic multicentric Castleman disease (iMCD) is still unknown. Due to a lack of uniform diagnostic criteria and a disease-specific International Classification of Diseases (ICD) code,…
Sudipto Mukherjee, MD, MPH, Ph.D., Director of Rare Cancers and Blood Diseases, at the Cleveland Clinic speaks about the Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy.Link to Article:https://doi.org/10.1182/bloodadvances.2021004441Points to Remember:* To calculate the incidence and prevalence of iMCD, a novel algorithm based on disease-specific ICD-10-CM codes and diagnostic criteria were developed.* Despite being the only FDA-approved medication, siltuximab is rarely used in iMCD patients.The epidemiology of HHV-8-deficient/idiopathic multicentric Castleman disease (iMCD) is still unknown. Due to a lack of uniform diagnostic criteria and a disease-specific International Classification of Diseases (ICD) code,…
Erin Frances Cobain, MD, Clinical Lecturer, University of Michigan Rogel Cancer Center speaks about the ASCOPubs Article – Tumor/normal Genomic Profiling In Patients With Metastatic Solid Tumors Identifies Pathogenic Germline Variants Of Therapeutic Importance.Link to Article:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1501Abstract:Background:Patients are frequently referred to clinical trials of targeted medicines based on tumor genetic profiling using next-generation sequencing (NGS). Incidental pathogenic germline variations (PGVs) are discovered during NGS testing of paired tumor/normal samples, which could have serious consequences for patients and their families.Methods:The Michigan Oncology Sequencing study sequenced the exome and transcriptome of matched tumor/normal samples for 1,015 patients with metastatic, resistant solid malignancies from…
Erin Frances Cobain, MD, Clinical Lecturer, University of Michigan Rogel Cancer Center speaks about the ASCOPubs Article – Tumor/normal Genomic Profiling In Patients With Metastatic Solid Tumors Identifies Pathogenic Germline Variants Of Therapeutic Importance.Link to Article:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1501Abstract:Background:Patients are frequently referred to clinical trials of targeted medicines based on tumor genetic profiling using next-generation sequencing (NGS). Incidental pathogenic germline variations (PGVs) are discovered during NGS testing of paired tumor/normal samples, which could have serious consequences for patients and their families.Methods:The Michigan Oncology Sequencing study sequenced the exome and transcriptome of matched tumor/normal samples for 1,015 patients with metastatic, resistant solid malignancies from…